Clinical Case Discussion Forum

Subscribe to the Clinical Case Discussion Forum

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Acute pancreatitis

Start
Prev
1
Next
End

Howard Saiontz
Topic Author

10 years 1 month ago #988 by Howard Saiontz

Acute pancreatitis was created by Howard Saiontz

I have a 52 y.o. male with newly dxed CML. A little over 1 wk. after starting Sprycel 100 mg qday his WBC is dropping nicely, but he has developed abdominal pain with a lipase of approx 7500 and an amylase of nearly 1000. A CT scan of abd/pelvis is c/w acute pancreatitis. There are no prior known risk factors for this complication, though a GI physician is being consulted. I am holding Sprycel pending rcovery from the pancreatitis, but any thoughts regarding rechallenging the pt. with the same dose vs. lowering the dose vs. substituting a different TKI?

Many thanks!

Hemant Malhotra
Topic Author

10 years 1 month ago #992 by Hemant Malhotra

Replied by Hemant Malhotra on topic Acute pancreatitis

DEAR HOWARD,
THANK YOU FOR POSTING THIS INTERESTING PROBLEM.
PANCREATITIS WITH DASATINIB IS MUCH LESS COMMON AS COMPARED TO WITH NILOTINIB. SUGGEST YOU RULE OUT OTHER CONTRIBUTING CAUSES LIKE HYPERTRIGLYCERIDEMIA/GALL STONE DISEASE/NIDDM ETC. WOULD START DASATINIB AFTER COMPLETE RESOLUTION OF THE PANCREATITIS AND WITH HALF DOSE 950 MG/DAY) WITH CLOSE MONITORING OF PANCREATIC ENZYMES AND ULTRASONOGRAPHY OF THE PANCREAS. WOULD INCREASE TO FULL DOSE OVER 15 DAYS IF NO EVIDENCE OF RECURRENCE OF THE PANCREATITIS. IF THE ENZYMES START INCREASING ON 50 MG/DAY, WOULD CONSIDER CHANGING TO IMATINIB (DEFINITELY NOT NILOTINIB).

(case repeated here for reader reference)
I have a 52 y.o. male with newly dxed CML. A little over 1 wk. after starting Sprycel 100 mg qday his WBC is dropping nicely, but he has developed abdominal pain with a lipase of approx 7500 and an amylase of nearly 1000. A CT scan of abd/pelvis is c/w acute pancreatitis. There are no prior known risk factors for this complication, though a GI physician is being consulted. I am holding Sprycel pending rcovery from the pancreatitis, but any thoughts regarding rechallenging the pt. with the same dose vs. lowering the dose vs. substituting a different TKI?

Many thanks!

Francisco Cervantes
Topic Author

10 years 1 month ago #993 by Francisco Cervantes

Replied by Francisco Cervantes on topic Acute pancreatitis

Dear colleague,

Pancreatitis is unusual under dasatinib. However, if there are not other contributing causes, I would think that the drug is clearly the trigger of this complication. Since there has been acute pancreatitis, and not just lipase or amylase increase, I would not rechallenge the patient with dasatinib. I would not try Nilotinib either, given the strong association of this drug with pancreatic abnormalities. Ponatinib is not available but if available it would be other TKI to avoid in case of pancreatitis. Therefore, after the resolution of the pancreatitis I would try imatinib. Bosutinib would be my second choice.

Francisco Cervantes

(case repeated here for reader reference)
I have a 52 y.o. male with newly dxed CML. A little over 1 wk. after starting Sprycel 100 mg qday his WBC is dropping nicely, but he has developed abdominal pain with a lipase of approx 7500 and an amylase of nearly 1000. A CT scan of abd/pelvis is c/w acute pancreatitis. There are no prior known risk factors for this complication, though a GI physician is being consulted. I am holding Sprycel pending rcovery from the pancreatitis, but any thoughts regarding rechallenging the pt. with the same dose vs. lowering the dose vs. substituting a different TKI?

Many thanks!

Jeff Lipton
Topic Author

10 years 1 month ago - 10 years 1 month ago #994 by Jeff Lipton

Replied by Jeff Lipton on topic Acute pancreatitis

Both Hemant and Francisco make excellent points. The teaching message here is that with all the drugs available, nothing is all or none in terms of adverse events/slide effects. If you look at the original Gleevec/Glivec product monograph for example, pleural effusions are described. Look at studies and monographs and you will find pancreatitis listed. Everything is relative. I would agree with the logic that nilotinib and ponatinib are the least desirable options and that imatinib and to a lesser extent bosutinib are the best choices, but the patient needs to watched very closely on starting anything.

(case repeated here for reader reference)
I have a 52 y.o. male with newly dxed CML. A little over 1 wk. after starting Sprycel 100 mg qday his WBC is dropping nicely, but he has developed abdominal pain with a lipase of approx 7500 and an amylase of nearly 1000. A CT scan of abd/pelvis is c/w acute pancreatitis. There are no prior known risk factors for this complication, though a GI physician is being consulted. I am holding Sprycel pending rcovery from the pancreatitis, but any thoughts regarding rechallenging the pt. with the same dose vs. lowering the dose vs. substituting a different TKI?

Many thanks!

Last edit: 10 years 1 month ago by Melissa Davis-Bishop.

Start
Prev
1
Next
End

Moderators: Nicola, arlene

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK